转移性结直肠癌中并发的 NRAS-BRAF 变异：突尼斯病例报告。

IF 1.8 4区医学 Q3 ONCOLOGY Anti-Cancer Drugs Pub Date : 2024-06-01 Epub Date: 2024-03-05 DOI:10.1097/CAD.0000000000001586

Hayet Douik, Ghada Sahraoui, Mohamed Jemaà, Raoudha Doghri, Lamia Charfi, Karima Mrad

{"title":"转移性结直肠癌中并发的 NRAS-BRAF 变异：突尼斯病例报告。","authors":"Hayet Douik, Ghada Sahraoui, Mohamed Jemaà, Raoudha Doghri, Lamia Charfi, Karima Mrad","doi":"10.1097/CAD.0000000000001586","DOIUrl":null,"url":null,"abstract":"Target therapy for metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RAS genes (KRAS/NRAS) are mutated in 40-60% of metastatic colorectal cancer and BRAF in 5-10%. The presence of a double mutation in RAS and BRAF is rare. Therefore, RAS and BRAF mutations were considered exclusive. Herein, we describe a novel concomitant NRAS/BRAF mutation identified in a series of 865 colorectal cancer patients.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"462-465"},"PeriodicalIF":1.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.\",\"authors\":\"Hayet Douik, Ghada Sahraoui, Mohamed Jemaà, Raoudha Doghri, Lamia Charfi, Karima Mrad\",\"doi\":\"10.1097/CAD.0000000000001586\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Target therapy for metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RAS genes (KRAS/NRAS) are mutated in 40-60% of metastatic colorectal cancer and BRAF in 5-10%. The presence of a double mutation in RAS and BRAF is rare. Therefore, RAS and BRAF mutations were considered exclusive. Herein, we describe a novel concomitant NRAS/BRAF mutation identified in a series of 865 colorectal cancer patients.\",\"PeriodicalId\":7969,\"journal\":{\"name\":\"Anti-Cancer Drugs\",\"volume\":\" \",\"pages\":\"462-465\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-Cancer Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/CAD.0000000000001586\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Cancer Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CAD.0000000000001586","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

转移性结直肠癌的靶向治疗需要确定 KRAS、NRAS 和 BRAF 的突变状态，以识别对抗 EGFR 治疗耐药的患者。40%-60%的转移性结直肠癌的 RAS 基因（KRAS/NRAS）发生突变，5%-10%的转移性结直肠癌的 BRAF 基因发生突变。RAS 和 BRAF 基因出现双重突变的情况非常罕见。因此，RAS 和 BRAF 突变被认为是排他性的。在此，我们描述了在一系列 865 例结直肠癌患者中发现的新型 NRAS/BRAF 并发突变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.

Target therapy for metastatic colorectal cancer needs the determination of KRAS, NRAS, and BRAF mutation status to identify patients resistant to anti-EGFR treatment. RAS genes (KRAS/NRAS) are mutated in 40-60% of metastatic colorectal cancer and BRAF in 5-10%. The presence of a double mutation in RAS and BRAF is rare. Therefore, RAS and BRAF mutations were considered exclusive. Herein, we describe a novel concomitant NRAS/BRAF mutation identified in a series of 865 colorectal cancer patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anti-Cancer Drugs 医学-药学

CiteScore

3.80

自引率

0.00%

发文量

244

审稿时长

3 months

期刊介绍： Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.